2023
Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2—functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer
Lustberg M, Wu X, Fernández-Martínez J, de Andrés-Galiana E, Philips S, Leibowitz J, Schneider B, Sonis S. Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2—functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer. Supportive Care In Cancer 2023, 31: 178. PMID: 36809570, PMCID: PMC11344472, DOI: 10.1007/s00520-023-07617-6.Peer-Reviewed Original ResearchMeSH KeywordsGenome-Wide Association StudyHumansNeoplasmsPeripheral Nervous System DiseasesPolymorphism, Single NucleotideTaxoidsConceptsGWAS dataSNP clustersFunctional analysisGO termsNon-protein coding genesGene Ontology termsGene Set Enrichment AnalysisCluster of SNPsNervous system developmentCoding genesRetinoic acid bindingOntology termsProtein kinase C bindingEnrichment analysisMetabolic processesGenesAcid bindingGlycosyltransferase activitySNPsPathological implicationsGWASC bindingGene signaturePhenotypeTransferase activityIdentification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial
Lustberg M, Wu X, Fernández-Martínez J, de Andrés-Galiana E, Philips S, Leibowitz J, Schneider B, Sonis S. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial. Supportive Care In Cancer 2023, 31: 139. PMID: 36707490, DOI: 10.1007/s00520-023-07595-9.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBreast NeoplasmsClinical Trials as TopicFemaleGenome-Wide Association StudyHumansPeripheral Nervous System DiseasesPolymorphism, Single NucleotideTaxoidsConceptsChemotherapy-induced peripheral neuropathyLarge cooperative group trialsCooperative group trialsIndependent patient cohortsCancer chemotherapy regimenCIPN riskCommon toxicitiesTaxane exposureChemotherapy regimenNeuropathy riskPeripheral neuropathyPatient cohortClinical trialsBreast cancerGroup trialsEffective interventionsPatientsRisk determinationInconsistent resultsECoGTrialsPresent studyRiskDiscriminatory powerHigh predictive accuracy
2017
Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm
Reinbolt R, Sonis S, Timmers C, Fernández‐Martínez J, Cernea A, de Andrés‐Galiana E, Hashemi S, Miller K, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm. Cancer Medicine 2017, 7: 240-253. PMID: 29168353, PMCID: PMC5773952, DOI: 10.1002/cam4.1256.Peer-Reviewed Original Research
2015
Risk factors for anthracycline-associated cardiotoxicity
Reinbolt R, Patel R, Pan X, Timmers C, Pilarski R, Shapiro C, Lustberg M. Risk factors for anthracycline-associated cardiotoxicity. Supportive Care In Cancer 2015, 24: 2173-2180. PMID: 26563179, PMCID: PMC4874738, DOI: 10.1007/s00520-015-3008-y.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsAnthracycline cardiotoxicityRisk factorsAlcoholic drinks/weekFemale breast cancer patientsHigher cardiotoxicity riskDrinks/weekModerate alcohol consumptionAnthracycline-associated cardiotoxicityBreast cancer patientsCases of cardiotoxicityMajor alleleEjection fractionPediatric patientsCancer patientsCardiotoxicity riskLower riskTherapeutic strategiesAlcohol consumptionCardiotoxicityMultivariate analysisLogistic regressionPatientsGenomic predictorsSignificant correlation